Cargando…
Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency
BACKGROUND: Daclizumab is a humanized monoclonal antibody that blocks CD25, the high affinity alpha subunit of the interleukin-2 receptor. Daclizumab therapy targets T regulatory cell and activated effector T cell proliferation to suppress autoimmune disease activity, in inflammatory conditions like...
Autores principales: | Watson, Leisa Rebecca, Slade, Charlotte A., Ojaimi, Samar, Barnes, Sara, Fedele, Pasquale, Smith, Prudence, Marum, Justine, Lunke, Sebastian, Stark, Zornitza, Hunter, Matthew F., Bryant, Vanessa L., Low, Michael Sze Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196561/ https://www.ncbi.nlm.nih.gov/pubmed/30377434 http://dx.doi.org/10.1186/s13223-018-0272-7 |
Ejemplares similares
-
Two neurologic facets of CTLA4-related haploinsufficiency
por: Ayrignac, Xavier, et al.
Publicado: (2020) -
A case of autoimmune enteropathy with CTLA4 haploinsufficiency
por: Miyazaki, Haruka, et al.
Publicado: (2022) -
Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report
por: Kohatsu, Kaori, et al.
Publicado: (2022) -
A Family with a Novel CTLA4 Haploinsufficiency Mutation and Neurological Symptoms
por: Grammatikos, Alexandros, et al.
Publicado: (2021) -
Prolonged Disease Course of COVID-19 in a Patient with CTLA-4 Haploinsufficiency
por: Hoffman, T. W., et al.
Publicado: (2023)